Clinical Trial Search

Primary: Change From Baseline in Plasma Glucose Concentration at 30 Minutes After IMP Injection — 102.3; 104.3 milligrams per deciliter (mg/dL)

Primary: Proportion of Patients With Therapeutic Failure — 3; 30 Participants

Primary: Kaplan-Meier Estimate of Progression-Free Survival by Independent Radiology/Clinical Review Committee Assessment in the Overall Population — 7.10; 8.30 months — p=0.468

Primary: Achievement of Scalp Investigator Global Assessment (S-IGA) "Success" at Week 8 — 66.4; 27.8 percentage of participants — p=<0.0001

Primary: Geometric Mean Titers of Anti-Human Papillomavirus Vaccine Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 (9vHPV) — 2198.5; 1806.8; 1517.6; 1138.2 mMU/mL

Primary: Participants With Solicited Local and Systemic AEs for 7 Days Following Vaccination — 153; 166; 136; 140 participants

Primary: Mean Change From Baseline in Number of Migraine Days Per Month From Week 9 to 12 of the Double-Blind Treatment (DBT) Phase — -2.4; -1.4 Days/month — p=0.0021

Primary: Change From Baseline to Week 13 in Average Worst Leg Pain Score During the Past 24 Hours Over the Previous 7 Days — -41.7; -34.2 units on a scale — p=0.0263

Primary: Percent Change From Baseline in 28-day Seizure Frequency for Primary Seizure Type During Double Blind Period — -7.50; 13.57 Percent change — p=0.0904

Primary: Absence of Anterior Chamber Cells at Visit 6. — 57.2; 24.0 percentage of study eyes — p=<0.0001

Primary: Geometric Mean Titer (GMT) of Anti-Hemagglutinin (HA) Antibody Levels as Measured by Hemagglutination Inhibition (HAI) — 147.49; 220.17; 137.90; 208.10 titer

Primary: Progression Free Survival (PFS) — 263.1; 229.1 Weeks — p=0.3296

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 61; 19; 38; 10 Participants

Primary: Change From Baseline in Serum Bile Acids — -104.00; -139.84; -57.97 micromole per liter (µmol/L)

Primary: Number of Participants With Urinary Retention — 0; 11; 74; 63 Participants